Cushing's Syndrome

Endocrinology and Metabolism Clinics of North America

Volumn 37, Issue 1, 2008, Pages 135-149

  Pivonello, Rosario ^a   De Martino, Maria Cristina ^a   De Leo, Monica ^a   Lombardi, Gaetano ^a   Colao, Annamaria ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENAL TUMOR; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CUSHING DISEASE; CUSHING SYNDROME; HUMAN; HYDROCORTISONE RELEASE; HYPOPHYSIS TUMOR; MORBIDITY; MORTALITY; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROGNOSIS; RARE DISEASE; REVIEW;

ADRENOCORTICOTROPIC HORMONE; CUSHING SYNDROME; ENZYME INHIBITORS; HUMANS; HYDROCORTISONE; NEUROTRANSMITTER AGENTS;

EID: 38349144642     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2007.10.010     Document Type: Review

References (55)

1. Newell-Price J., Bertagna X., Grossman A.B., et al. Cushing's syndrome. Lancet 367 (2006) 1605-1617
2. Lindholm J., Juul S.J., Jorgensen J.O., et al. Incidence and late prognosis of Cushing's syndrome: a population-based study. Clin Endocrinol Metab 86 (2001) 117-123
3. Catargi B., Rigalleau V., Poussin A., et al. Occult Cushing's syndrome in type-2 diabetes. J Clin Endocrinol Metab 88 (2003) 5808-5813
4. Pecori Giraldi F., Moro M., and Cavagnini F. Gender-related differences in the presentation and course of Cushing's disease. J Clin Endocrinol Metab 88 (2003) 1554-1558
5. Pivonello R., Faggiano A., Lombardi G., et al. The metabolic syndrome and cardiovascular risk in Cushing's syndrome. Endocrinol Metab Clin North Am 34 (2005) 327-339
6. Faggiano A., Pivonello R., Spiezia S., et al. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab 88 (2003) 2527-33
7. Faggiano A., Melis D., Alfieri R., et al. Sulfur amino acids in Cushing's disease: insight in homocysteine and taurine levels in patients with active and cured disease. J Clin Endocrinol Metab 90 (2005) 6616-6622
8. Colao A., Pivonello R., Spiezia S., et al. Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. J Clin Endocrinol Metab 84 (1999) 2664-2672
9. Faggiano A., Pivonello R., Melis D., et al. Nephrolithiasis in Cushing's disease: prevalence, etiopathogenesis, and modification after disease cure. J Clin Endocrinol Metab 88 (2003) 2076-2080
10. Di Somma C., Pivonello R., Loche S., et al. Severe impairment of bone mass and turnover in Cushing's disease: comparison between childhood-onset and adulthood-onset disease. Clin Endocrinol (Oxf) 56 (2002) 153-158
11. Tauchmanovà L., Pivonello R., Di Somma C., et al. Bone demineralization and vertebral fractures in endogenous cortisol excess: role of disease etiology and gonadal status. J Clin Endocrinol Metab 91 (2006) 1779-1784
12. Di Somma C., Colao A., Pivonello R., et al. Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing's disease. Clin Endocrinol (Oxf) 48 (1998) 655-662
13. Forget H., Lacroix A., and Cohen H. Persistent cognitive impairment following surgical treatment of Cushing's syndrome. Psychoneuroendocrinology 27 (2002) 367-383
14. Bourdeau I., Bard C., Noel B., et al. Loss of brain volume in endogenous Cushing's syndrome and its reversibility after correction of hypercortisolism. J Clin Endocrinol Metab 87 (2002) 1949-1954
15. Lindsay J.R., Nansel T., Baid S., et al. Long-term impaired quality of life in Cushing's syndrome despite initial improvement after surgical remission. J Clin Endocrinol Metab 91 (2006) 447-453
16. Arnaldi G., Angeli A., Atkinson A.B., et al. Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 88 (2003) 5593-5602
17. Newell-Price J., Trainer P., Besser G.M., et al. The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr Rev 19 (1998) 647-672
18. Boscaro M., Barzon L., and Sonino N. The diagnosis of Cushing's syndrome: atypical presentations and laboratory shortcomings. Arch Intern Med 160 (2000) 3045-3053
19. Papanicolaou D.A., Mullen N., Kyrou I., et al. Nighttime salivary cortisol: a useful test for the diagnosis of Cushing's syndrome. J Clin Endocrinol Metab 87 (2002) 4515-4521
20. Yanovski J.A., Cutler Jr. G.B., Chrousos G.P., et al. Corticotropin-releasing hormone stimulation following low-dose dexamethasone administration. A new test to distinguish Cushing's syndrome from pseudo-Cushing's states. JAMA 269 (1993) 2232-2238
21. Pecori Giraldi F., Pivonello R., Ambrogio A.G., et al. The dexamethasone-suppressed corticotropin-releasing hormone stimulation test and the desmopressin test to distinguish Cushing's syndrome from pseudo-Cushing's states. Clin Endocrinol (Oxf) 66 (2007) 251-257
22. Invitti C., Pecori Giraldi F., de Martin M., et al. Diagnosis and management of Cushing's syndrome: results of an Italian multicentre study. Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis. J Clin Endocrinol Metab 84 (1999) 440-448
23. Oldfield E.H., Doppman J.L., Nieman L.K., et al. Petrosal sinus sampling with and without corticotropin-releasing hormone for the differential diagnosis of Cushing's syndrome. N Engl J Med 325 (1991) 897-905
24. Colao A., Faggiano A., Pivonello R., et al. Study Group of the Italian Endocrinology Society on the Pathophsiology of the Hypothalamic-Pituitary-Adrenal Axis. Inferior petrosal sinus sampling in the differential diagnosis of Cushing's syndrome: results of an Italian multicenter study. Eur J Endocrinol 144 (2001) 499-507
25. Rees D.A., Hanna F.W., Davies J.S., et al. Long-term follow-up results of transsphenoidal surgery for Cushing's disease in a single centre using strict criteria for remission. Clin Endocrinol (Oxf) 56 (2002) 541-551
26. Atkinson A.B., Kennedy A., Wiggamvan M.I., et al. Long-term remission rates after pituitary surgery for Cushing's disease: the need for long-term surveillance. Clinical Endocrinol (Oxf) 63 (2005) 549-559
27. Pereira A.M., van Aken M.O., van Dulken H., et al. Long-term predictive value of postsurgical cortisol concentrations for cure and risk of recurrence in Cushing's disease. J Clin Endocrinol Metab 88 (2003) 5858-5864
28. Yap L.B., Turner H.E., Adams C.B., et al. Undetectable postoperative cortisol does not always predict long-term remission in Cushing's disease: a single centre audit. Clin Endocrinol (Oxf) 56 (2002) 25-31
29. Porpiglia F., Fiori C., Bovio S., et al. Bilateral adrenalectomy for Cushing's syndrome: a comparison between laparoscopy and open surgery. J Endocrinol Invest 27 (2004) 654-658
30. Assie G., Bahurel H., Bertherat J., et al. The Nelson's syndrome revisited. Pituitary 7 (2004) 209-215
31. Miller J.W., and Crapo L. The medical treatment of Cushing's syndrome. Endocr Rev 14 (1993) 443-458
32. Nieman L.K. Medical therapy of Cushing's disease. Pituitary 5 (2002) 77-82
33. Lamberts S.W., and Birkenhäger J.C. Bromocriptine in Nelson's syndrome and Cushing's disease. Lancet 2 (1976) 811
34. Lamberts S.W., Klijn J.G., de Quijada M., et al. The mechanism of the suppressive action of bromocriptine on adrenocorticotropin secretion in patients with Cushing's disease and Nelson's syndrome. J Clin Endocrinol Metab 51 (1980) 307-311
35. Invitti C., De Martin M., Danesi L., et al. Effect of injectable bromocriptine in patients with Cushing's disease. Exp Clin Endocrinol Diabetes 103 (1995) 266-271
36. Heaney A.P., Fernando M., Yong W.H., et al. Functional PPARgamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med 8 (2002) 1281-1287
37. Heaney A.P., Fernando M., and Melmed S. PPAR-gamma receptor ligands: novel therapy for pituitary adenomas. J Clin Invest 111 (2003) 1381-1388
38. Ambrosi B., Dall'Asta C., Cannavo S., et al. Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease. Eur J Endocrinol 151 (2004) 173-178
39. Pecori Giraldi F., Scaroni C., Arvat E., et al. Effect of protracted treatment with rosiglitazone, a PPARgamma agonist, in patients with Cushing's disease. Clin Endocrinol (Oxf) 64 (2006) 219-224
40. Suri D., and Weiss R.E. Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing's disease. J Clin Endocrinol Metab 90 (2005) 1340-1346
41. Munir A., Song F., Ince P., et al. Ineffectiveness of rosiglitazone therapy in Nelson's syndrome. J Clin Endocrinol Metab 92 (2007) 1758-1763
42. Petrossians P., Ronci N., Valdés Socin H., et al. ACTH silent adenoma shrinking under cabergoline. Eur J Endocrinol 144 (2001) 51-57
43. T'Sjoen G., Defeyter I., van de Saffele J., et al. Macroprolactinoma associated with Cushing's disease, successfully treated with cabergoline. J Endocrinol Invest 25 (2002) 172-175
44. Pivonello R., Ferone D., de Herder W.W., et al. Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab 89 (2004) 2452-2462
45. Pivonello R, De Martino MC, Faggiano A, et al. Cabergoline treatment in Cushing's disease: effect on hypertension, glucose metabolism and dyslipidemia. Presented at the 9th European Congress of Endocrinology, Budapest, Hungary, April 29-May 2, 2007.
46. Pivonello R., Faggiano A., Di Salle F., et al. Complete remission of Nelson's syndrome after 1-year treatment with cabergoline. J Endocrinol Invest 22 (1999) 860-865
47. Casulari L.A., Naves L.A., Mello P.A., et al. Nelson's syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment. Horm Res 62 (2004) 300-305
48. Shraga-Slutzky I., Shimon I., and Weinshtein R. Clinical and biochemical stabilization of Nelson's syndrome with long-term low-dose cabergoline treatment. Clinical and biochemical stabilization of Nelson's syndrome with long-term low-dose cabergoline treatment. Pituitary 9 (2006) 151-154
49. Hofland L.J., van der Hoek J., Feelders R., et al. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 152 (2005) 645-654
50. Boscaro M, Atkinson A, Bertherat J, et al. SOM230 Cushing's disease study group. Early data on the efficacy and safety of the novel multi-ligand somatostatin analog, SOM230, in patients with Cushing's disease. Presented at the 87th Annual Meeting of the Endocrine Society. San Diego (CA), June 4-7, 2005.
51. Pivonello R., Ferone D., Lamberts S.W., et al. Cabergoline plus lanreotide for ectopic Cushing's syndrome. N Engl J Med 352 (2005) 2457-2458
52. Pivonello R., Ferone D., de Herder W.W., et al. Dopamine receptor expression and function in corticotroph ectopic tumors. J Clin Endocrinol Metab 92 (2007) 66-69
53. Paez-Pereda M., Kovalovsky D., Hopfner U., et al. Retinoic acid prevents experimental Cushing syndrome. J Clin Invest 108 (2001) 1123-1131
54. Estrada J., Boronat M., Mielgo M., et al. The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease. N Engl J Med 336 (1997) 172-177
55. Sheehan J.M., Vance M.L., Sheehan J.P., et al. Radiosurgery for Cushing's disease after failed transsphenoidal surgery. J Neurosurg 93 (2000) 738-742